ZNTL News & Events

Zentalis Pharmaceuticals provided a corporate update and highlighted key milestones and expected momentum in the azenosertib development program for 2026. 2025 Accomplishments: Completed enrollment in DENALI Part 2a, supporting registration-intended development of azenosertib; Aligned with the FDA on confirmatory ASPENOVA Phase 3 trial design; Strong data across three trials in PROC established a solid foundation for the lead indication in Cyclin E1-positive platinum-resistant ovarian cancer; Maintained a strong cash position supporting an estimated runway into late 2027 following strategic restructuring to focus pipeline and resources. Anticipated 2026 Milestones: DENALI Part 2a dose confirmation expected in first half of 2026; Confirmatory ASPENOVA Phase 3 trial initiation expected in first half of 2026; DENALI Part 2 topline readout on track and expected by year end 2026

"We are pleased with our continued disciplined execution of the DENALI clinical trial this quarter, supporting late-stage development of azenosertib as a potential treatment for Cyclin E1-positive platinum-resistant ovarian cancer, and positioning us for an anticipated topline data readout by year end 2026. Our engagement with trial investigators and presence at medical conferences is very encouraging and continues to support our development strategy," said Julie Eastland, Chief Executive Officer of Zentalis. "With $280.7 million in cash providing runway into late 2027, we maintain a robust financial foundation to deliver on our azenosertib objectives."

Anthony Letai, a cancer researcher and oncologist at the Dana-Farber Cancer Institute and Harvard University and a member of the scientific advisory board at Zentalis, has emerged as a top candidate to serve as the next director of the National Cancer Institute, STAT News' Matthew Herper and Angus Chen report, citing multiple sources with direct knowledge of the situation. Cancer scientists have expressed relief that Letai would lead the cancer research office, as they describe him as both kind and a highly qualified scientist, the authors note.